PharmaMar - Aplidin and Zepsyre milestones coming up
PharmaMar investors await two key events that are expected in the next few months. The European Committee for Medicinal Products for Human Use...
61 Views
Preparing for ovarian Phase III data
Data from the 443-patient Phase III CORAIL study of Zepsyre® (lurbinectedin, PM01183) in platinum-resistant ovarian cancer is expected in H217...
64 Views
We see value in self-commercialisation
At its recent R&D day in New York, PharmaMar flagged endometrial cancer as a likely fourth indication for lurbinectedin (data to be presented...
42 Views
Strong newsflow expected in 2017
PharmaMar is approaching two key milestones in H217: an approval decision for Aplidin for multiple myeloma in Europe; and Phase III results for...
34 Views
Japan licence deal highlights PM1183 potential
PharmaMar has capped off a strong performance in 2016 by signing a licence deal with Chugai for lurbinectedin (PM1183) in Japan, including €30m...
39 Views